Book a demo
Research & KnowledgeEvent: August 31, 2026

GelTech Labs published a study developed a temperature-responsive liposomal formulation that forms a depot after subcutaneous injection using buprenorphine as a model drug.

Published

Signal category

Research & Knowledge

Quote

A recent study developed a temperature-responsive liposomal formulation that forms a depot after subcutaneous injection.

Taylor Barkdoll|GelTech Labs team

Company

GelTech Labs

Helping labs develop better hydrogels, faster with robotic automation tools.

Industry
Biotechnology Research
Location
San Diego, US
Company size
13 employees

Revolutionizing hydrogel testing through automation. Hydrogels are next-gen materials enabling breakthroughs in drug delivery, wound care, tissue engineering, cosmetics, contact lenses, and more—yet testing their properties remains largely manual, slow, and error-prone. GelTech’s flagship product, Carousel, is the first automation tool designed specifically for hydrogel swelling and degradation testing—cutting costs, boosting reproducibility, and accelerating innovation across the $5B polymer lab market. Backed by $1M in funding, NSF I-Corps, and partnerships with academic and enterprise leaders, we are setting a new industry standard and paving the way for smarter R&D, Quality Control and faster commercialization of hydrogel-based products.

Founded 2023

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.

GelTech Labs published a study developed a temperature-responsive liposomal formulation that forms a depot after subcutaneous injection using buprenorphine as a model drug. | SeedOps